Studies also show that IL‐24 treatment triggers phosphorylation of eiF2α on the serine 51 residue in prostate cancer (Sauane et al. 2008), melanoma, breast, and cervical cancer cells (Persaud et al. 2017). This evidence concerns the gene IL24 and prostate cancer.